➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Medtronic
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

MOXATAG Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Moxatag, and when can generic versions of Moxatag launch?

Moxatag is a drug marketed by Pragma and is included in one NDA. There are three patents protecting this drug.

This drug has eleven patent family members in six countries.

The generic ingredient in MOXATAG is amoxicillin. There are forty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amoxicillin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Moxatag

A generic version of MOXATAG was approved as amoxicillin by TEVA on December 22nd, 1992.

  Get Started for $10

US Patents and Regulatory Information for MOXATAG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 DISCN Yes No   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 DISCN Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MOXATAG

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008   Get Started for $10   Get Started for $10
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008   Get Started for $10   Get Started for $10
Pragma MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MOXATAG

Country Patent Number Estimated Expiration
European Patent Office 1969134   Get Started for $10
Australia 2003261339   Get Started for $10
Australia 2003261359   Get Started for $10
European Patent Office 1968586   Get Started for $10
European Patent Office 1545465   Get Started for $10
World Intellectual Property Organization (WIPO) 2004012704   Get Started for $10
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Dow
Express Scripts
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.